AstraZeneca/$AZN
1D1W1MYTD1Y5YMAX
Capital at risk
About AstraZeneca
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
- Ticker
- $AZN
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 96,100
- Headquarters
- Cambridge, United Kingdom
- Website
- www.astrazeneca.com
AstraZeneca Metrics
BasicAdvanced
$252B
24.38
$6.68
0.22
$3.23
1.30%
Price and volume
Market cap
$252B
Beta
0.22
52-week high
$212.71
52-week low
$153.41
Average daily volume
3.4M
Dividend rate
$3.23
Financial strength
Current ratio
0.886
Quick ratio
0.664
Long term debt to equity
0.516
Total debt to equity
0.642
Dividend payout ratio (TTM)
45.73%
Interest coverage (TTM)
10.40%
Profitability
EBITDA (TTM)
19,904
Gross margin (TTM)
81.69%
Net profit margin (TTM)
17.02%
Operating margin (TTM)
23.86%
Effective tax rate (TTM)
16.95%
Revenue per employee (TTM)
$640,000
Management effectiveness
Return on assets (TTM)
8.02%
Return on equity (TTM)
21.96%
Valuation
Price to earnings (TTM)
24.385
Price to revenue (TTM)
4.114
Price to book
3.74
Price to tangible book (TTM)
-21.86
Price to free cash flow (TTM)
40.397
Free cash flow yield (TTM)
2.48%
Free cash flow per share (TTM)
4.032
Dividend yield (TTM)
1.98%
Forward dividend yield
1.30%
Growth
Revenue change (TTM)
8.61%
Earnings per share change (TTM)
25.84%
3-year revenue growth (CAGR)
11.32%
10-year revenue growth (CAGR)
9.81%
3-year earnings per share growth (CAGR)
19.13%
10-year earnings per share growth (CAGR)
14.33%
3-year dividend per share growth (CAGR)
3.66%
10-year dividend per share growth (CAGR)
1.44%
Upcoming events
No upcoming events
AstraZeneca News
AllArticlesVideos
Funds containing AstraZeneca
AllGBPEURUSD
Fund name | Fund size | $AZN weighting |
|---|---|---|
Vanguard FTSE 100£VUKE | £4.8B | 7.27% |
Amundi STOXX Europe 600 ESG€C6E | €735M | 2.32% |
Amundi STOXX Europe 600£MEUD | £6.6B | 2.17% |
Vanguard FTSE Developed Europe£VEUA | £2.6B | 2.05% |
Amundi Index MSCI Europe£CE2D | £5.1B | 2.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.